Scholarlink

<p>Follow-up care for endometrial carcinoma should be guideline-based and carried out in close interdisciplinary collaboration among the involved specialties. Its aims are the early detection of recurrence, the management of treatment- and surgery-related sequelae, and the provision of psychosocial support for patients. Risk stratification is playing an increasingly important role in structuring follow-up care. In stages I–II, the focus is on a&#xa0;structured medical history and gynecologic examination. These assessments are performed every 6&#xa0;months for up to 5&#xa0;years after completion of treatment. In patients with high-risk or advanced tumors, follow-up is conducted more frequently—usually every 3&#xa0;months during the first 3&#xa0;years—and may be supplemented by extended imaging. With the introduction of increasingly complex treatment concepts, particularly immune checkpoint inhibitors, the management of treatment-related adverse effects is becoming increasingly important.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Leitlinienkonforme Nachsorge beim Endometriumkarzinom – modifiziert durch Risikoadaptation, Supportivtherapie und Survivorship-Programme

  • 期刊论文

  • 发表日期：

    2026年6月29日

查看全文
  • Julia Gocke,
  • Vanessa Karlen,
  • Matthias W. Beckmann,
  • Patrik Pöschke,
  • Julius Emons

摘要

Follow-up care for endometrial carcinoma should be guideline-based and carried out in close interdisciplinary collaboration among the involved specialties. Its aims are the early detection of recurrence, the management of treatment- and surgery-related sequelae, and the provision of psychosocial support for patients. Risk stratification is playing an increasingly important role in structuring follow-up care. In stages I–II, the focus is on a structured medical history and gynecologic examination. These assessments are performed every 6 months for up to 5 years after completion of treatment. In patients with high-risk or advanced tumors, follow-up is conducted more frequently—usually every 3 months during the first 3 years—and may be supplemented by extended imaging. With the introduction of increasingly complex treatment concepts, particularly immune checkpoint inhibitors, the management of treatment-related adverse effects is becoming increasingly important.